Assoc. Prof. TUĞRUL PÜRNAK

Personal Information

Office Phone: +90 312 305 1712 Extension: 1712
Email: tugrul.purnak@hacettepe.edu.tr
Web: https://avesis.hacettepe.edu.tr/tugrul.purnak

Education Information

Post Doctorate of Medicine, Ankara Numune Hastanesi, Gastroenteroloji, Gastroenteroloji, Turkey 2008 - 2011
Expertise In Medicine, Hacettepe University, Tıp, İç Hastalıkları, Turkey 2002 - 2007
Undergraduate, Ankara University, Tıp Fakültesi, Tıp, Turkey 1995 - 2001

Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Internal Diseases , Gastroenterology and Hepatology

Academic Titles / Tasks

Associate Professor, Hacettepe University, Hacettepe Tıp Fakültesı, 2012 - Continues

Published journal articles indexed by SCI, SSCI, and AHCI

I. **Prevalence and significance of antimitochondrial antibodies in autoimmune hepatitis (AIH): Results from a large multicentre study of the International AIH Group**
Gatselis N. K., Zachou K., Loza A. J. M., Cançado E. L. R., Arinaga-Hino T., Muratori P., Efe C., Floreani A., Invernizzi P., Takahashi A., et al.
European Journal of Internal Medicine, vol.116, pp.43-50, 2023 (SCI-Expanded)

II. **Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome**
Efe C., Kulkarni A. V., Terziroli Beretta-Piccoli B., Magro B., Friedrich Staettermayer A., Cengiz M., Clayton-Chubb D., Lammert C., Bernsmeier C., Gul O., et al.
HEPATOLOGY, vol.76, no.6, pp.1576-1586, 2022 (SCI-Expanded)

III. **Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis**
Efe C., Lammert C., Tascilar K., Dhanasekaran R., Ebik B., Higuera-de la Tijera F., Caliskan A. R., Peralta M., Gerussi A., Massoumi H., et al.
LIVER INTERNATIONAL, vol.42, no.3, pp.607-614, 2022 (SCI-Expanded)

IV. **Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study**
Efe C., Dhanasekaran R., Lammert C., Ebik B., Higuera-de la Tijera F., Aloman C., Caliskan A. R., Peralta M., Gerussi A., Massoumi H., et al.
HEPATOLOGY, vol.73, no.6, pp.2099-2109, 2021 (SCI-Expanded)

V. **Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome**
Efe C., Torgutalp M., Henriksson I., Alalkim F., Lytvyak E., Trivedi H., Eren F., Fischer J., Chayanupatkul M., Coppo C.,

et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol.36, no.4, pp.936-942, 2021 (SCI-Expanded)

VI. **Fasciola As An Unusual Cause of Cholangitis**
Efe C., Umay A., PÜRNAK T.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, vol.19, no.4, 2021 (SCI-Expanded)

VII. **Retrospective Evaluation of Hepatitis C Awareness in Turkey Through Two Decades**
BALABAN H. Y., DAĞ O., Alp A., Tseveldorj N., Vahabov C., GÖKTAŞ M. A., PÜRNAK T., Hascelik G., DEMİR H., SİVRİ B., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.32, no.1, pp.88-96, 2021 (SCI-Expanded)

VIII. **High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation**
Pape S., Gevers T. J. G., Vrolijk J. M., van Hoek B., Bouma G., van Nieuwkerk C. M. J., Taubert R., Jaeckel E., Manns M. P., Papp M., et al.
LIVER INTERNATIONAL, vol.40, no.9, pp.2164-2171, 2020 (SCI-Expanded)

IX. **What Is the Optimal Dose of Predniso(lo)ne for Induction of Remission in Patients With Autoimmune Hepatitis?**
Efe C., Ozaslan E., PÜRNAK T.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, vol.18, no.8, pp.1896-1897, 2020 (SCI-Expanded)

X. **Rapid Response to Treatment of Autoimmune Hepatitis Associated With Remission at 6 and 12 Months**
Pape S., Gevers T. J. G., Vrolijk J. M., van Hoek B., Bouma G., van Nieuwkerk C. M. J., Taubert R., Jaeckel E., Manns M. P., Papp M., et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, vol.18, no.7, pp.1609-1621, 2020 (SCI-Expanded)

XI. **Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis**
Efe C., Tascilar K., Henriksson I., Lytvyak E., Alalkim F., Trivedi H., EREN F., Eliasson J., Beretta-Piccoli B. T., Fischer J., et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY, vol.114, no.7, pp.1101-1108, 2019 (SCI-Expanded)

XII. **An unusual cause of gastrointestinal bleeding in an elderly patient**
KÖKLÜ H., Dincer A., KUMBASAR U., DOĞRUL A. B., PÜRNAK T.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.29, no.5, pp.610-612, 2018 (SCI-Expanded)

XIII. **Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis**
Efe C., Al Taii H., Ytting H., Aehling N., Bhanji R. A., Hagstrom H., PÜRNAK T., Muratori L., Werner M., Muratori P., et al.
DIGESTIVE DISEASES AND SCIENCES, vol.63, no.5, pp.1348-1354, 2018 (SCI-Expanded)

XIV. **Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Therapy-Related Severe Anemia**
KÖKLÜ H., PÜRNAK T., Tseveldorj N., ALTAN E., ŞİMŞEK H.
ANNALS OF PHARMACOTHERAPY, vol.52, no.4, pp.397-398, 2018 (SCI-Expanded)

XV. **Ulcerated colonic mass mimicking malignancy in an elderly patient**
KÖKLÜ H., Imamoglu E., Tseveldorj N., SÖKMENSÜER C., PÜRNAK T., KAV T.
GERIATRICS & GERONTOLOGY INTERNATIONAL, vol.18, no.4, pp.651-653, 2018 (SCI-Expanded)

XVI. **Second-line immunosuppressants for autoimmune hepatitis**
Efe C., Ozaslan E., PÜRNAK T.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.30, no.4, pp.490-491, 2018 (SCI-Expanded)

XVII. **Methotrexate in the Treatment of Autoimmune Hepatitis**
Efe C., Ozaslan E., PÜRNAK T.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, vol.16, no.1, pp.149, 2018 (SCI-Expanded)

XVIII. **Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis**
Efe C., Hagstrom H., Ytting H., Bhanji R. A., Muller N. F., Wang Q., PÜRNAK T., Muratori L., Werner M., Marschall H., et

al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, vol.15, no.12, pp.1950-1957, 2017 (SCI-Expanded)

XIX. **Treatment Response and Outcome with Two Different Prednisolone Regimens in Autoimmune Hepatitis**
PÜRNAK T., Efe C., KAV T., Wahlin S., Ozaslan E.
DIGESTIVE DISEASES AND SCIENCES, vol.62, no.10, pp.2900-2907, 2017 (SCI-Expanded)

XX. **AN UNUSUAL CAUSE OF ANEMIA IN AN ELDER: ISOLATED SPLENIC HEMANGIOMATOSIS AND HEMORRHAGIC TELANGIECTASIA**
ÖZTÜRK Ö., KÖKLÜ S., BAŞAR Ö., PÜRNAK T., YÜKSEL O.
GASTROENTEROLOGY NURSING, vol.39, no.4, pp.317-318, 2016 (SCI-Expanded)

XXI. **Inflammation and chemerin in colorectal cancer**
Erdogan S., YILMAZ F. M., Yazici O., Yozgat A., Sezer S., Ozdemir N., Uysal S., PÜRNAK T., Sendur M. A., Ozaslan E.
TUMOR BIOLOGY, vol.37, no.5, pp.6337-6342, 2016 (SCI-Expanded)

XXII. **CROHN DISEASE PRESENTED WITH A GIANT COLONIC MASS**
ÖZTÜRK Ö., KÖKLÜ S., BAŞAR Ö., PÜRNAK T., YÜKSEL O.
GASTROENTEROLOGY NURSING, vol.39, no.3, pp.235-237, 2016 (SCI-Expanded)

XXIII. **Angiotensin-converting enzyme for noninvasive assessment of liver fibrosis in autoimmune hepatitis**
Efe C., Cengiz M., Kahramanoglu-Aksoy E., YILMAZ B., Ozseker B., Beyazit Y., Tanoglu A., PÜRNAK T., KAV T., Turhan T., et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.27, no.6, pp.649-654, 2015 (SCI-Expanded)

XXIV. **Overview of Venous Thrombosis in Inflammatory Bowel Disease**
PÜRNAK T., YÜKSEL O.
INFLAMMATORY BOWEL DISEASES, vol.21, no.5, pp.1195-1203, 2015 (SCI-Expanded)

XXV. **An Unusual Presentation of Malignant Melanoma: Amelanotic Gastric Metastasis**
ÖZTÜRK Ö., BAŞAR Ö., KÖKLÜ S., YÜKSEL O., PÜRNAK T., SÖKMENSÜER C.
AMERICAN JOURNAL OF GASTROENTEROLOGY, vol.110, no.3, pp.476-477, 2015 (SCI-Expanded)

XXVI. **Nitric oxide is a potential mediator of hepatic inflammation and fibrogenesis in autoimmune hepatitis**
Beyazit Y., Efe C., Tanoglu A., Purnak T., Sayilir A., Taskiran I., Kekilli M., Turhan T., Ozaslan E., Wahlin S.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.50, no.2, pp.204-210, 2015 (SCI-Expanded)

XXVII. **Low Serum Vitamin D Levels Are Associated with Severe Histological Features and Poor Response to Therapy in Patients with Autoimmune Hepatitis**
EFE C., KAV T., AYDIN C., Cengiz M., IMGA N. N., Purnak T., Smyk D. S., Torgutalp M., TURHAN T., Ozenirler S., et al.
DIGESTIVE DISEASES AND SCIENCES, vol.59, no.12, pp.3035-3042, 2014 (SCI-Expanded)

XXVIII. **The Comparison of Two Different 5.5 Fr Sphincterotomes for Selective Cannulation of the Common Bile Duct: A Prospective, Randomized Study**
Ozaslan E., Purnak T., Efe C., Ozaslan N. G., Cengiz M.
DIGESTIVE DISEASES AND SCIENCES, vol.59, no.12, pp.3078-3084, 2014 (SCI-Expanded)

XXIX. **Pregnancy in women with primary biliary cirrhosis**
Efe C., Kahramanoglu-Aksoy E., YILMAZ B., Ozseker B., Takci S., Roach E. C., PÜRNAK T., Kay T., Ozaslan E., Wahlin S.
AUTOIMMUNITY REVIEWS, vol.13, no.9, pp.931-935, 2014 (SCI-Expanded)

XXX. **Vitamin D Levels in Patients With Chronic Hepatitis B**
Efe C., PÜRNAK T., Ozaslan E.
HEPATOLOGY, vol.60, no.2, pp.768, 2014 (SCI-Expanded)

XXXI. **Factors Associated With Response to Therapy and Outcome of Patients With Primary Biliary Cirrhosis With Features of Autoimmune Hepatitis**
Ozaslan E., Efe C., Heurgue-Berlot A., KAV T., Masi C., Purnak T., Muratori L., ÜSTÜNDAĞ Y., Bresson-Hadni S., Thiefin G., et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, vol.12, no.5, pp.863-869, 2014 (SCI-Expanded)

XXXII. **Sequential presentation of primary biliary cirrhosis and autoimmune hepatitis**
Efe C., Ozaslan E., Heurgue-Berlot A., KAV T., Masi C., Purnak T., TORĞUTALP M., Muratori L., Bresson-Hadni S.,

Thiefin G., et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.26, no.5, pp.532-537, 2014 (SCI-Expanded)

XXXIII. **Liver and Atherosclerosis**
PÜRNAK T., Efe C., BAŞAR Ö.
GASTROENTEROLOGY, vol.146, no.5, pp.1427, 2014 (SCI-Expanded)

XXXIV. **Late autoimmune hepatitis after hepatitis C therapy**
Efe C., Heurgue-Berlot A., Ozaslan E., Purnak T., Thiefin G., ŞİMŞEK H., Wahlin S.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.25, no.11, pp.1308-1311, 2013 (SCI-Expanded)

XXXV. **Authors' reply: 'Mean platelet volume could be a promising biomarker to monitor dietary compliance in celiac disease'**
Purnak T., Beyazit Y., Efe C., Ozaslan E., Yuksel O., Altiparmak E.
UPSALA JOURNAL OF MEDICAL SCIENCES, vol.118, no.3, pp.208, 2013 (SCI-Expanded)

XXXVI. **Diagnostic difficulties, therapeutic strategies, and performance of scoring systems in patients with autoimmune hepatitis and concurrent hepatitis B/C**
Efe C., Wahlin S., Ozaslan E., Purnak T., Muratori L., Quarneti C., TATAR G., ŞİMŞEK H., Muratori P., Schiano T. D.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.48, no.4, pp.504-508, 2013 (SCI-Expanded)

XXXVII. **Mean platelet volume is increased in chronic hepatitis C patients with advanced fibrosis**
Purnak T., Olmez S., Torun S., Efe C., Sayilir A., Ozaslan E., Tenlik I., Kalkan I. H., Beyazit Y., Yuksel O.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, vol.37, no.1, pp.41-46, 2013 (SCI-Expanded)

XXXVIII. **Long-term Efficacy and Safety of Lamivudine, Entecavir, and Tenofovir for Treatment of Hepatitis B Virus-Related Cirrhosis**
Koklu S., Tuna Y., Gulsen M. T., Demir M., Koksal A. S., KOÇKAR M. C., Aygun C., Coban S., Ozdil K., Ataseven H., et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, vol.11, no.1, pp.88-94, 2013 (SCI-Expanded)

XXXIX. **Reply to Dr Onal: the importance of serum angiotensin-converting enzyme level in chronic hepatitis B**
Purnak T., Beyazit Y., Efe C., Ozaslan E.
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, vol.13, no.4, pp.504, 2012 (SCI-Expanded)

XL. **The involvement of nitric oxide in the physiopathology of hepatoportal sclerosis**
Purnak T., Beyazit Y., Ibis M., Koklu S., Efe C., Ozaslan E., Ciftci A., Tenlik I.
CLINICAL BIOCHEMISTRY, vol.45, pp.1450-1454, 2012 (SCI-Expanded)

XLI. **Mean platelet volume as a non-invasive marker of fibrosis in chronic hepatitis C**
Purnak T., Beyazit Y., Efe C., Ozaslan E.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, vol.36, no.4, 2012 (SCI-Expanded)

XLII. **Serum angiotensin-converting enzyme level as a marker of fibrosis in patients with chronic hepatitis B**
Purnak T., Beyazit Y., Oztas E., Yesil Y., Efe C., Torun S., Celik T., Tenlik I., Kurt M., Ozaslan E.
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, vol.13, no.2, pp.244-249, 2012 (SCI-Expanded)

XLIII. **Chronic hepatitis C, inflammatory bowel disease and interferon therapy**
Efe C., Roach E. C., Purnak T., Ozaslan E.
JOURNAL OF CROHNS & COLITIS, vol.6, no.5, pp.626-627, 2012 (SCI-Expanded)

XLIV. **Liver biopsy is a superior diagnostic method in some patients showing the typical laboratory features of autoimmune hepatitis**
Efe C., Ozaslan E., Purnak T., Ozseker B., KAV T., BAYRAKTAR Y.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, vol.36, no.2, pp.185-188, 2012 (SCI-Expanded)

XLV. **Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome**
Efe C., Ozaslan E., KAV T., Purnak T., Shorbagi A., ÖZKAYAR Ö., Berlot A. H., SÖKMENSÜER C., Muratori P.
AUTOIMMUNITY REVIEWS, vol.11, no.5, pp.330-334, 2012 (SCI-Expanded)

XLVI. **Cerebral abscesses-a stroke mimic**
Purnak T., Ozaslan E., Efe C.
AGE AND AGEING, vol.40, no.5, pp.645-646, 2011 (SCI-Expanded)

XLVII. **Recent Insights Into the Relationship Between Inflammatory Liver Diseases and Atherosclerosis**
Purnak T., Efe C., Beyazit Y., Ozaslan E., Astan R., Milanlioglu A., Ozbalkan Z., Rizzo M.
JOURNAL OF INVESTIGATIVE MEDICINE, vol.59, no.6, pp.904-911, 2011 (SCI-Expanded)

XLVIII. **Mean platelet volume could be a promising biomarker to monitor dietary compliance in celiac disease**
Purnak T., Efe C., Yuksel O., Beyazit Y., Ozaslan E., Altiparmak E.
UPSALA JOURNAL OF MEDICAL SCIENCES, vol.116, no.3, pp.208-211, 2011 (SCI-Expanded)

XLIX. **A Comparison of Jurkat Cell-Reactive Anti-T Lymphocyte Globulin and Fetal Anti-Thymocyte Globulin Preparations in the Treatment of Aplastic Anemia**
Serefhanoglu S., Buyukasik Y., Purnak T., Goker H., Sayinalp N., Haznedaroglu I. C., Ozcebe O. I.
MEDICAL PRINCIPLES AND PRACTICE, vol.20, no.4, pp.341-344, 2011 (SCI-Expanded)

L. **A novel fungal pathogen under the spotlight - Acremonium spp. associated fungaemia in an immunocompetent host**
PÜRNAK T., Beyazit Y., Sahin G. O., Shorbagi A., AKOVA M.
MYCOSES, vol.54, no.1, pp.78-80, 2011 (SCI-Expanded)

LI. **Albumin-bound paclitaxel (ABI-007; Abraxane) in the management of basal-like breast carcinoma**
Altundag K., Dede D. S., Purnak T.
JOURNAL OF CLINICAL PATHOLOGY, vol.60, no.8, pp.958, 2007 (SCI-Expanded)

LII. **Hormone receptor status as a prognostic factor in breast cancer patients with hepatic metastases treated by liver resection**
Purnak T., Altundag K.
ANNALS OF SURGERY, vol.246, no.2, pp.338, 2007 (SCI-Expanded)

LIII. **Hormone receptor status as a prognostic factor affecting the outcome of brain metastases**
Harputluoglu H., Purnak T., Altundag K.
SUPPORTIVE CARE IN CANCER, vol.15, no.3, pp.347, 2007 (SCI-Expanded)

LIV. **Concomitant use of antioxidants may decrease the efficacy of cisplatin in cancer patients**
Purnak T., Cengiz M., Altundag K.
MEDICAL HYPOTHESES, vol.68, no.5, pp.1177, 2007 (SCI-Expanded)

LV. **Global warming may increase the incidence and geographic range of Crimean-Congo Hemorrhagic Fever**
Purnak T., Selvi N. A., Altundag K.
MEDICAL HYPOTHESES, vol.68, no.4, pp.924-925, 2007 (SCI-Expanded)

LVI. **Alterations in the 'local umbilical cord blood renin-angiotensin system' during pre-eclampsia**
Acar K., Beyazit Y., Sucak A., Haznedaroglu I. C., Aksu S., Tuncer S., Ozturkkan D., Danisman N., Purnak T., Misirlioglu M., et al.
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, vol.86, no.10, pp.1193-1199, 2007 (SCI-Expanded)

Refereed Congress / Symposium Publications in Proceedings

I. **Hepatitis C Awareness Survey: Retrospective Evaluation of HCV Tests between 2000-2017**
Balaban Y. H., DAĞ O., Alp A., PÜRNAK T., GÖKTAŞ M. A., Tseveldor N., DEMİR H., Koklu H., Vahabov C., SİVRİ B., et al.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San-Francisco, Costa Rica, 9 - 13 November 2018, vol.68

II. **KRONİK GRANÜLOMATOZ HASTALIK VE YAYGIN DEĞİŞKEN İMMÜN YETMEZLİK HASTASINDA İNFLAMATUAR BAĞIRSAK HASTALIĞI OLGUSU**
EYÜPOĞLU N. D., ÇALIK BAŞARAN N., ÖZIŞIK L., ÖZ Ş. G., PÜRNAK T., ÖCAL S., ÇAĞDAŞ AYVAZ D. N., TEZCAN F. İ.
19. İç Hastalıkları Kongresi, Turkey, 11 - 15 October 2017

III. **Tacrolimus or Mycophenylate mofetil as a second-line therapeutic options in patients with Autoimmune Hepatitis: An international multicentre observational study**
Efe C., Hagstrom H., Bhanji R. A., Mueller N. F., Wang Q., PÜRNAK T., Muratori L., Werner M., Marschall H., Muratori P., et al.
66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Costa Rica, 13 - 17 November 2015, vol.62

IV. **Paraneoplastik intestinal dismotilite ve gastroparezi ile prezente olan küçük hücreli akciğer kanseri olgusu**
ŞENER Y. Z., ÖZIŞIK L., ÇALIK BAŞARAN N., PÜRNAK T., TÜRKER F. A.
16. Ulusal İç Hastalıkları Kongresi, Antalya, Turkey, 15 - 19 October 2014, pp.235-236

Supported Projects

PÜRNAK T., ÖZTÜRK Y., SÖKMENSÜER C., Project Supported by Higher Education Institutions, Kronik hepatit B ilintili ileri evre fibrozis ve sirotik hastalarda hepatoselüler karsinoma gelişimi riskinin erken evrede tespit edilmeye çalışılması ve bu hastaların yönetimi, 2018 - 2020
PÜRNAK T., Project Supported by Higher Education Institutions, Türk popülasyonunda otoimmün hepatit hastalarının tedavi sonuçları, 2017 - 2017
PÜRNAK T., Project Supported by Higher Education Institutions, Viral hepatit tedavisinde kullanılan ilaçların kanser hastalarında etkinliği, 2015 - 2017
PÜRNAK T., TUBITAK Project, Oddi sfinkter disfonksiyonu gelişimine yatkınlığı olan durumların ve tedavi yanıtını etkileyen faktörlerin belirlenmesi, 2015 - 2016

Metrics

Publication: 60
Citation (WoS): 494
Citation (Scopus): 104
H-Index (WoS): 12
H-Index (Scopus): 4